Phase 2 clinical study titled ‘A Phase 2, Randomized, Double-Blind, Active-Controlled, Dose-Finding Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants ...

The 21-valent pneumococcal conjugate vaccine V116 is well tolerated in adults living with HIV and induces immunity to all 21 ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 1 study titled ‘A Study to Learn About ...

Infectious disease researchers at Case Western Reserve University's School of Medicine in Cleveland found that the vaccine, ...

Several observational analyses suggest higher cardiovascular and dementia risks in those with and without HIV who get ...

A series of recommended shots that health providers administer to children as they age has been a recent target of President ...

The adult-specific 21-valent pneumococcal conjugate vaccine was well tolerated and immunogenic across all 21 serotypes in patients with HIV infection.

Vaccine awareness, safety, and addressing misinformation are all important to improve adherence and public health outcomes, ...

Eligibility for this vaccination is suddenly a timely question. A senior health editor reports on her real-time experience.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive results from the Phase 3 STRIDE-13 trial evaluating CAPVAXIVE® (Pneumococcal 21-valent Conjugate ...

The shingles vaccine may cut dementia risk by up to 33%, per new research. Here, experts explain how it works and what it may ...

The investigators used a test-negative case-control design to estimate the vaccine effectiveness (VE) of the RSVpreF (Abrysvo ...